“六步八法”手法联合阿仑膦酸钠治疗膝关节退行性病变

目的探讨"六步八法"手法联合阿仑膦酸钠治疗膝关节退行性病变临床疗效。方法随机将2012-03—2014-03间收治的60例膝关节退行性病变患均分为对照组和观察组,每组30例。对照组行阿仑膦酸钠治疗,观察组则给予"六步八法"手法联合阿仑膦酸钠治疗。对2组临床疗效、治疗前后VAS及JOA评分进行比较。结果观察组治疗总有效率96.67%,明显高于对照组(80.00%)。两组比较,差异有统计学意义。2组治疗后VAS及JOA评分比较差异有统计学意义(P<0.05)。结论 "六步八法"手法联合阿仑膦酸钠治疗膝关节退行性病变安全有效,能明显改善患者膝关节功能,值得临床推广。     

金锁固精丸加味联合654-2穴位注射治疗遗精40例临床观察

目的 观察金锁固精丸加味联合山莨菪碱(654-2)穴位注射治疗遗精的临床疗效.方法 选取遗精患者80例,随机分为观察组、对照组,各40例.观察组口服金锁固精丸加味联合654-2穴位注射,对照组给予舒乐安定片和谷维素片口服,观察对比两组的临床疗效.结果 观察组总有效率为90.0％,对照组总有效率为72.5％,两组对比差异有统计学意义(P＜0.05).结论 金锁固精丸加味口服联合654-2穴位注射治疗遗精疗效显著,值得临床推广.     

复方丹参滴丸对2型糖尿病肾病患者尿微量白蛋白及微炎症状态的影响

目的：探讨复方丹参滴丸对早期2型糖尿病肾病(DN)患者尿微量白蛋白及微炎症状态的影响。方法60例早期2型DN患者随机分为A、B两组,各30例,B组给予控制血糖及血管紧张素受体阻滞剂等常规治疗,A组患者在此基础上加用复方丹参滴丸治疗,疗程均为16周。选择30例健康体检者纳入对照组,比较DN患者与对照组血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平,并比较治疗前后A、B两组患者尿微量白蛋白排泄率(UAER)及血清hs-CRP、TNF-α、IL-6水平的变化。结果 DN患者血清hs-CRP、TNF-α及IL-6水平均较对照组明显升高,差异均有统计学意义(P<0.05);治疗后A、B两组患者UAER及血清hs-CRP、TNF-α及IL-6水平均明显下降,且治疗后A组上述指标明显低于B组,差异均有统计学意义(P<0.05)。结论复方丹参滴丸可改善DN患者的微炎症状态,降低尿微量白蛋白水平,延缓肾脏病进展。     

长春西汀联合复方丹参滴丸治疗小脑动脉梗死合并冠心病的临床观察

为观察长春西汀联合复方丹参滴丸治疗小脑动脉梗死合并冠心病患者的临床效果,选取126例小脑动脉梗死合并冠心病例患者进行观察,其中63例给予长春西汀注射液治疗(对照组),另外63例给予长春西汀注射液联合复方丹参滴丸治疗(观察组)。比较两组患者临床疗效,对比治疗前后神经功能、日常生活能力、凝血功能、血液动力学指标、左心室功能指标及脑钠肽和碱性磷酸酶水平。结果显示,与对照组比较,观察组的临床总有效率为显著增高(77.78% vs 95.24%,P＜0.05);神经功能、日常生活能力、凝血功能、血液动力学及左心室功能及脑钠肽和碱性磷酸酶改善程度均显著升高(P＜0.05)。结果说明长春西汀联合复方丹参滴丸治疗小脑动脉梗死合并冠心病疗效显著,可能与进一步改善患者神经功能及血液动力学有关。     

复方丹参滴丸联合曲美他嗪治疗不稳定型心绞痛的临床疗效观察

目的评价复方丹参滴丸联合曲美他嗪治疗不稳定型心绞痛的临床疗效。方法将100例不稳定型心绞痛患者随机分为观察组和对照组各50例,对照组予硝酸甘油、低分子肝素钠、消心痛、拜阿司匹林等抗凝、抗血小板、降脂、扩血管治疗,观察组同时联合复方丹参滴丸0.25 g口服,曲美他嗪20 mg口服,3次/d,连用4周;比较两组患者治疗后的临床疗效及治疗前后SBP、DBP、HR及TC、TG、LDL-C、HDL-C的变化情况。结果观察组治疗的总有效率高于对照组,疗效明显优于对照组(P0.05)。治疗后两组患者SBP、DBP、HR、TC、TG、LDL-C水平较治疗前降低,HDL-C较治疗前升高,且观察组患者治疗后的SBP、DBP、HR、TC、LDL-C水平明显低于对照组(P0.05)。结论复方丹参滴丸联合曲美他嗪治疗不稳定型心绞痛疗效确切,能明显改善患者的临床症状、降低血脂水平、降低血压、改善患者的心率,值得临床推广和应用。     

The Influence of Maxillary Incisor Inclination on Arch Length

Abstract

This ex vivo study was designed to investigate Andrew's hypothesis that there is a space implication when incisors are torqued correctly. A working model was constructed to allow acrylic typodont incisors of varying known values of inclination to be substituted into the model. The arch lengths of the various 'set-ups' were measured using a reflex microscope linked to a PC. In order to quantify the space requirement of clinical relevance for adequate incisor torque, the method was repeated by substituting replicas of patients' 'natural' incisors.

For both acrylic and natural incisors it was found that, as the inclination of the teeth increased, there was an increase in all arch lengths, this being greater for the natural incisors. This larger increase for the natural incisors was related not only to their increased size, but was also dependent on the morphology of the incisor. Those incisors which were parallel-sided showed the greatest increase in arch length, whereas the incisors that were relatively triangular in shape showed the smallest increase.

When the inclination of an 'average' set of 21|12 is increased by 5 degrees, an increase in the arch length of approximately 1 mm may be expected.     

阿德福韦酯联合安络化纤丸对乙型肝炎早中期肝硬化治疗效果评价

[目的]评价阿德福韦酯(ADV)联合安络化纤丸治疗乙型肝炎早中期肝硬化的疗效.[方法]145例乙型肝炎早中期肝硬化患者分为对照组(32例)、ADV组(53例)及联合用药组(60例).对照组采用常规护肝及对症治疗;ADV组在对照组基础上加口服ADV 10 mg,1次/d;联合用药组在ADV组基础上加口服安络化纤丸3g,疗程均为1年.比较3组治疗后肝功能、血清肝纤维化指标、乙型肝炎病毒(HBV)-DNA水平、Child-Pugh分值及门静脉压力指标变化.[结果]3组患者治疗后肝功能均不同程度的改善,联合用药组和ADV组肝功能改善优于对照组;联合用药组与ADV组血清白蛋白、球蛋白比较差异有统计学意义(P＜0.01);联合用药组和ADV组肝纤维化指标、HBV-DNA水平和Child-Pugh分值较对照组明显下降,联合用药组肝纤维化指标下降优于ADV组,联合用药组Child-Pugh 分值(5.02±0.76)明显低于ADV组(5.49±1.13),P＜0.01;治疗后联合用药组门静脉内径、脾静脉内径及脾脏厚度较对照组和ADV组明显下降,ADV组脾脏厚度缩小(P＜0.05).[结论]ADV联合安络化纤丸在改善乙型肝炎早中期肝硬化患者肝功能,降低其Child-Pugh评分、肝纤维化指标、门静脉压力指标及HBVDNA水平均有较好的效果.